Hunt­ing new deals, Eli Lil­ly bud­dies up on di­a­betes R&D with $55M pact

New Eli Lil­ly CEO David Ricks has an­oth­er deal to re­port.

Just a few months af­ter com­plet­ing a pact to ac­quire CoLu­cid’s mi­graine drug in a $960 mil­lion buy­out, the phar­ma gi­ant has front­ed $55 mil­lion to launch a new col­lab­o­ra­tion with the Swiss biotech Key­Bio­science on a class of dual amylin-cal­ci­tonin re­cep­tor ag­o­nist drugs aimed at amp­ing up in­sulin sen­si­tiv­i­ty and spurring weight loss for di­a­bet­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER